AAN 2022 | Assessing behavioral adverse events in patients taking brivaracetam
Kimford Meador, MD, FAAN, Stanford University, Stanford, CA, presents results from a retrospective study assessing the habituation of adverse events in patients with seizures receiving brivaracetam. Whilst brivaracetam is effective and well tolerated, side effects relating behavioral disorders did not habituate in the same fashion as cognitive effects such as mental acuity, which typically disappear over time. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Disclosures
Research support from the National Institutes of Health and Eisai Inc; the Epilepsy Study Consortium pays Dr. Meador’s university for his research consultant time related to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, UCB Pharma, and Vivus Pharmaceuticals.
